193 related articles for article (PubMed ID: 37726751)
1. Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis.
Strauss T; Günther C; Schnabel A; Wolf C; Hahn G; Lee-Kirsch MA; Brück N
Pediatr Rheumatol Online J; 2023 Sep; 21(1):104. PubMed ID: 37726751
[TBL] [Abstract][Full Text] [Related]
2. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
Paik JJ; Lubin G; Gromatzky A; Mudd PN; Ponda MP; Christopher-Stine L
Clin Exp Rheumatol; 2023 Mar; 41(2):348-358. PubMed ID: 35766013
[TBL] [Abstract][Full Text] [Related]
3. Lung infection or inflammation-a puzzling case of MDA-5 associated juvenile dermatomyositis.
Vuppala A; Sondhi M; Umer S
Pediatr Rheumatol Online J; 2023 Dec; 21(1):147. PubMed ID: 38124190
[TBL] [Abstract][Full Text] [Related]
4. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.
Ll Wilkinson MG; Deakin CT; Papadopoulou C; Eleftheriou D; Wedderburn LR
Pediatr Rheumatol Online J; 2021 Sep; 19(1):146. PubMed ID: 34563217
[TBL] [Abstract][Full Text] [Related]
6. Cardiac involvement in a case of juvenile dermatomyositis with positive anti-melanoma differentiation associated protein 5 antibody.
Kaplan MM; Çelikel E; Güngörer V; Ekici Tekin Z; Gürsu HA; Polat SE; Cinel G; Çelikel Acar B
Int J Rheum Dis; 2023 Aug; 26(8):1582-1585. PubMed ID: 36852875
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
8. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
[TBL] [Abstract][Full Text] [Related]
9. [Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor].
Jalles C; Deroux A; Tardieu M; Lugosi M; Viel S; Benveniste O; Colombe B
Rev Med Interne; 2020 Jun; 41(6):421-424. PubMed ID: 32192753
[TBL] [Abstract][Full Text] [Related]
10. The arthritis of inflammatory childhood myositis syndromes.
Tse S; Lubelsky S; Gordon M; Al Mayouf SM; Babyn PS; Laxer RM; Silverman ED; Schneider R; Feldman BM
J Rheumatol; 2001 Jan; 28(1):192-7. PubMed ID: 11196524
[TBL] [Abstract][Full Text] [Related]
11. The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
Cancarini P; Nozawa T; Whitney K; Bell-Peter A; Marcuz JA; Taddio A; Guo J; Dover S; Feldman BM
Semin Arthritis Rheum; 2022 Dec; 57():152104. PubMed ID: 36183479
[TBL] [Abstract][Full Text] [Related]
12. Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review.
Stewart JA; Price T; Moser S; Mullikin D; Bryan A
Pediatr Rheumatol Online J; 2022 Feb; 20(1):16. PubMed ID: 35193600
[TBL] [Abstract][Full Text] [Related]
13. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
14. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease.
Chan Ng PLP; Mopur A; Goh DYT; Ramamurthy MB; Lim MTC; Lim LK; Ooi PL; Ang EY
Int J Rheum Dis; 2022 Feb; 25(2):228-231. PubMed ID: 34882988
[TBL] [Abstract][Full Text] [Related]
15. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
Kim H
Expert Rev Clin Immunol; 2024 Jun; 20(6):589-602. PubMed ID: 38299575
[TBL] [Abstract][Full Text] [Related]
16. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Rapidly Progressive Interstitial Lung Disease in Juvenile Dermatomyositis.
Ciaglia K; Ghawji M; Caraballo M; Sloan E
Pediatrics; 2024 Mar; 153(3):. PubMed ID: 38361479
[TBL] [Abstract][Full Text] [Related]
18. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
19. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Yu Z; Wang L; Quan M; Zhang T; Song H
Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
[TBL] [Abstract][Full Text] [Related]
20. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
Wu JQ; Lu MP; Reed AM
World J Pediatr; 2020 Feb; 16(1):31-43. PubMed ID: 31556011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
